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A B S T R A C T
Purpose: Sodium valproate, which is commonly repacked to assist with adherence to ensure seizure
control, is hygroscopic and therefore sensitive to moisture. The aim of this study was thus to determine
the stability implications of removing the enteric coated tablets from their original packaging and
repackaging into a Dose Administration Aid (DAA) with storage under various environmental conditions.
Methods: Physicochemical stability of enteric coated sodium valproate tablets repackaged into a DAA
and stored at controlled room temperature, accelerated and refrigerated conditions was evaluated for 28
days. A validated high performance liquid chromatography method was used for the quantitation of the
drug content.
Results: Although the chemical stability (sodium valproate between 95 and 105% of labelled content)
was maintained for 28 days for all storage conditions, for those tablets stored under accelerated
conditions the integrity of the enteric coat was compromised after only 8 days.
Conclusions: Repackaging of enteric coated sodium valproate should be undertaken with caution and be
informed by storage climate. This is particularly relevant for those patients living in hot, humid
environments where they should be advised to store their DAA in a refrigerator.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is a chronic condition with effective seizure control
reliant on adherence to a daily dosage regimen [7,11,22]. This
presents a challenge for both patients and health care professionals
with non adherence increasing the public health burden associated
with both hospital admissions and costs [10,19].
Dose Administration Aids (DAAs), also known as Multi-
compartment Compliance Aids (MCCA or MCA) or monitored
dosage systems (MDS), are designed to assist patients in managing
their medicines by organising individual doses according to the
prescribed dosing schedule throughout the day [17,34]. Examples
of these devices include Nomad [28], Venalink [32], WebsterPak
[33], EasyBLIST [8], and MedicoPak [21]. In addition to DAAs
provided by pharmacies, repackaging companies supply repack-
aged medicines in strip type packaging for distribution to
pharmacies and/or patients include Thrifty White Pharmacy* Corresponding author. Tel.: +61 7 4781 6423; fax: +61 7 4781 5356.
E-mail address: Beverley.Glass@jcu.edu.au (B. Glass).
http://dx.doi.org/10.1016/j.seizure.2015.07.007
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights re[29], APHS (Australian Pharmaceutical Healthcare Systems) [2],
and MPS (Medication Packaging Systems Australia) [23].
Medicines are expected to meet their speciﬁcation for identity,
purity, quality and strength throughout their deﬁned storage
period. Stability of a medicine is conﬁrmed by the manufacturer for
the duration of the shelf-life of the product, provided that the
medicine remains in the original packaging and is stored under
speciﬁc conditions. Although DAAs might assist in managing
medicine regimens, repackaging, which requires removal from the
original packaging, invalidates the manufacturers stability guar-
antee. Generally manufacturers tend to discourage repackaging of
medication as there is little supporting stability data available
[6]. Very few studies have been reported in the literature on the
stability of medicines repackaged in DAAs [3,13,14,16,18,24,25].
This is particularly important for the antiepileptic drug, sodium
valproate, which is known to be unstable in the presence of moisture
due to its hygroscopic nature. Sodium valproate is available as an
oral liquid, injectable product and a tablet [1], with some tablets
containing an enteric coat, which reduces the gastrointestinal
symptoms associated with this active ingredient [20].
Some drug substances are particularly sensitive to the effects of
moisture. Exposure to these conditions during storage in a DAA,served.
Fig. 1. Visible rupturing of enteric coating after storage at 40 8C; 75% RH for eight
days.
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humidity (RH), may result in the chemical or physical stability
being compromised. Guidelines [26,27,31] generally advise against
repackaging hygroscopic medicines into DAAs.
In recent times, anecdotal evidence has suggested that the
integrity of sodium valproate tablets repackaged in DAAs has been
compromised. Thus the primary aim of this study was to
investigate the stability of enteric coated sodium valproate tablets
repackaged in DAAs and stored under ambient and accelerated
environmental conditions, with a view to providing patients advice
regarding appropriate storage of their medicine.
2. Material and methods
Physicochemical studies were performed on 200 mg enteric
coated (EC) tablets (Epilim EC200, Sanoﬁ-Aventis) repackaged in a
DAA (WebsterPak1). The DAAs were stored at controlled room
temperature (25  2 8C), accelerated (40  2 8C; 75  1.5% RH) and
refrigerated (5  3 8C) conditions, as per ICH guidelines [15], for
28 days. The results were compared to control samples immediately
removed from the manufacturer’s original packaging. All samples
were chosen at random from the respective packaging (DAA and
control) and had a remaining shelf-life of at least one year at the time
of sampling. Physical characteristics of the tablets, including weight
uniformity, physical appearance, thickness, hardness, friability,
disintegration and dissolution rates, were evaluated according to
British Pharmacopoeia (BP) compendial requirements [5] and
chemical stability was conﬁrmed by high performance liquid
chromatography (HPLC). Percentage relative standard deviations
were determined for representation of accuracy in the measurement.
IBM SPSS Statistics (version 21) was used for ANOVA analysis to
determine the level of signiﬁcance (p < 0.05) of results obtained.
2.1. Physical stability
Physical tests were performed on the tablets according to
compendial requirements [5,30]. Appearance was determined
organoleptically by comparison to the original samples. Tablet
weight uniformity was determined using an AND HM-200
analytical balance. Tablet hardness and thickness was determined
using a VK 200 tester. Tablet friability was determined using a
Vankel (VK) dual drum friabilator. A maximum loss of weight that
is not greater than 1% is considered to be acceptable.
Disintegration was determined using a VK 100 disintegration
tester as per a modiﬁed method for delayed-release tablets
described in the USP [30]. Six tablets from each storage condition
were exposed initially to simulated gastric ﬂuid (pH 1.2) at
37  0.5 8C for 1 h, with subsequent exposure in simulated intestinal
ﬂuid prepared without pancreatin (pH 6.8) under the same
conditions. The standard is met if no disintegration occurs in the
simulated gastric ﬂuids and complete disintegration occurs in the
simulated intestinal ﬂuids for all tablets.
Dissolution tests were performed according to the BP method
(method B) described for a delayed-release solid dosage forms on a
BP Apparatus II (paddle apparatus) (VK 7000) maintained at
37  0.5 8C. Tablets were initially exposed to an acidic environment
(0.1 M hydrochloric acid at pH 1.2) for 2 h at 50 rpm, removed and
then placed in a buffer solution (phosphate buffer at pH 6.8) for
45 min at 100 rpm. Samples of the dissolution ﬂuids were taken after
the acidic-stage and at the end of the buffer-stage and analysed using
the HPLC method described below.
2.2. Chemical stability
A Varian Prostar system consisting of a 210 solvent delivery
module, 410 autosampler and a 325 ultraviolet detector wasused to quantify sodium valproate. A Waters mBondapak C18
(4.6  250 mm) reverse-phase column (maintained at 30 8C) was
selected as the stationary phase. The mobile phase consisted of
potassium dihydrogen orthophosphate and acetonitrile (40:60)
adjusted to pH 3.0 with orthophosphoric acid (Univar, Australia). A
detection wavelength of 220 nm was used. An injection volume of
50 mL was used with a ﬂow rate of 1 mL/min. Data were analysed
using Varian Star Chromatography Workstation (version 6.41). A
calibration curve for sodium valproate was constructed from 20 to
500 mg/mL (r2 = 0.999). Standards were prepared in phosphate
buffer at pH 6.8 and subsequently acidiﬁed (0.1 M hydrochloric
acid at pH 1.2). Tablets were not crushed for sampling purposes to
avoid the sampling error associated with the tablet coating.
Triplicate whole tablets were placed in 100 mL phosphate buffer,
sonicated for 10 min, and diluted appropriately in buffer to prepare
a solution containing approximately 0.1 mg/mL sodium valproate.
A 5.0 mL sample was then acidiﬁed using 0.12 mL 5 M HCl and
ﬁltered through a 0.45 mm ﬁlter (Millipore) prior to analysis.
2.3. Statistical methods
The Kruskal–Wallis statistical analysis test was used to analyse
the results of the dissolution testing after storage under the
different conditions. Findings were subsequently subjected to post
hoc comparisons using Dunn’s test. For all cases the level of
signiﬁcance was 0.05.
3. Results
3.1. Physical stability
No changes to tablet appearance were seen for those tablets
stored repackaged under refrigerated and controlled room
temperature conditions for 28 days. However, for those tablets
stored under accelerated conditions of temperature and humidity,
rupturing of the tablet coat was observed after 8 days (Fig. 1). No
further physical tests were able to be performed on tablets stored
at accelerated conditions for a period greater than 8 days. The
enteric coat is designed to remain intact until the tablet reaches the
small intestine to avoid the gastrointestinal symptoms associated
with sodium valproate.
A slight increase in tablet weight and thickness was observed
for those tablets stored repackaged under accelerated conditions
(Fig. 2). The BP compendial requirements for friability of uncoated
tablets were met under all storage conditions, with a weight loss of
less than 1% for all tablets.
When compared to control samples, tablet hardness decreased
by 9.1% for those tablets stored at controlled room temperature for
28 days, and 33.4% for those stored under refrigerated conditions
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Fig. 2. Effect of exposure to various storage conditions on (A) tablet hardness and (B)
weight and thickness. Number in parentheses = days of test. Weight (n = 20),
hardness (n = 10), thickness (n = 10); mean  2SD.
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showed a 34.4% decrease in hardness, which a 62.0% decrease after
8 days. In the previous study [18], tablets stored repackaged under
accelerated conditions were too soft to be tested appropriately after
3 days. The enteric coat may therefore provide slightly improved
resistance to elevated conditions of humidity and temperature. It
should also be noted that the relative humidity in the refrigerator
was monitored using a data logger (Tinytag Plus), which recorded
temperature and humidity at 5-min intervals throughout the
speciﬁed time period, and found to vary greatly with an average
RH of 68.4%. The increased exposure to humidity in the refrigerator
may explain the decrease in tablet hardness.
The USP compendial requirements for disintegration are met if
no disintegration occurs in the simulated gastric ﬂuid, with
subsequent complete disintegration occurring in the simulated
intestinal ﬂuid. The requirements were met for all storage conditions
except for those stored under accelerated conditions for eight days,
where disintegration of tablets began in the simulated gastric ﬂuid.
The BP method B test for dissolution requires that each tablet
should release no more than 10% of active ingredient in the acidic
environment over a period of 2 h, after which and no less than 80%
must be released after 45 min in buffer solution. The requirements
were met for all tablets (Table 1). Dissolution studies were notTable 1
Effect of exposure to various storage conditions on the dissolution of sodium
valproate tablets repackaged in DAAs.
Storage conditions % Dissolved
(acid conditions)
% Dissolved
(buffer)
Time = 0 None 103.4  2.6
28 days (25 8C; 60% RH) None 102.3  2.3
28 days (5  3 8C) None 91.7  3.8
5 days (40 8C; 75% RH) 1.3  0.2 97.6  3.7
Values are expressed as mean  95% CI (n = 6).performed on those tablets stored at accelerated conditions for
8 days since they did not pass the disintegration test.
The Kruskal–Wallis statistical analysis was performed on the
above results of the percentage of sodium valproate that was
dissolved after 45 min in buffer. This was done in order to compare
the dissolution behaviour of the control tablets and the tablets after
storage in refrigerated, ambient or accelerated conditions using the
null hypothesis that there is no difference in dissolution behaviour
between the four conditions. After ranking the results and
performing the analysis, the Hcalc value was calculated to be
63.9. Since there were four treatment groups, each consisting of six
observations with a signiﬁcance level of 0.05, the Hcrit value was
seen to be 7.815. As the value for Hcrit is smaller than that of Hcalc
the null hypothesis can be accepted in that there is no signiﬁcant
difference between the dissolution behaviour of the control tablets
and that of the tablets after storage in the three various conditions.
Post hoc analysis using Dunn’s Test was also performed comparing
the dissolution behaviour of the control tablets with the behaviour
of the tablets after storage in the three conditions separately. A
standard error of 4.08 was calculated and values for Qcalc and Qcrit
were determined. It was found that none of three conditions differed
in dissolution behaviour in comparison to the control tablets since in
each case the value of Qcalc was found to be less than the value
found for Qcrit allowing the null hypotheses of no differences in
behaviour to be accepted. This illustrates that there is little
variability of the tablets tested in terms of their dissolution proﬁles
supporting the fact that repackaging is safe for tablets stored in the
various conditions tested for the time periods speciﬁed.
3.2. Chemical stability
The retention time for sodium valproate was 6.8 min. Linearity
was conﬁrmed over the concentration range used (r2 = 0.999).
Concentrations of sodium valproate in the samples were determined
from respective peak areas in relation to constructed standard curves
and then converted to a percentage of the initial sodium valproate
concentration. The results showed that the sodiumvalproate content
was within the range (95–105% of labelled amount) speciﬁed in the
BP monograph [4] under all storage conditions.
4. Discussion
This study has shown that it is acceptable to repackage enteric
coated sodium valproate tablets for up to 28 days under either
refrigerated (5  3 8C) or controlled room temperature (25  2 8C)
conditions. However, storage under accelerated conditions of
humidity and temperature is not advised, with the enteric coat of
the tablet rupturing after 8 days.
These ﬁndings concur with a recent study reporting on the
chemical and physical stability of 100 mg immediate-release
sodium valproate tablets repackaged into DAAs (WebsterPak1),
stored under accelerated (40 8C; 75% RH), room temperature
(25 8C; 60% RH) and refrigerated (2–8 8C) conditions [18]. It was
found that although the sodium valproate drug content remained
within the acceptable range of 95–105% for all conditions
(chemically stable) unacceptable weight variation and variable
dissolution proﬁles resulted during the 56-day storage period. In
fact, after seven days under accelerated conditions, tablets only
attained 60% dissolution after 45 min, failing the BP compendial
test which requires that no less than 80% of stated drug amount be
dissolved after 45 min. Tablets became unusable after ten days
with implied variability in terms of bioavailability and conse-
quences for the patients’ level of seizure control. Fig. 3 highlights
the effect of humidity on the physical stability of the tablets,
particularly for those stored under accelerated conditions.
Fig. 3. Sodium valproate tablets after 21 days of storage at accelerated (left),
refrigerated (middle) and controlled room temperature (right) conditions.
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dissolution proﬁle, a component of physical stability. Carbamaze-
pine, another well-established drug used to treat epilepsy, has a
history of irregular drug performance and clinical failures, with
several reports showing high dissolution variability in carbamaz-
epine tablets on the market world-wide and even among
carbamazepine tablets of the same brand [12]. In 1990, the Food
and Drug Administration (FDA) reported that carbamazepine
tablets can lose one third of their effectiveness if exposed to
moisture due to tablet hardening, poor dissolution and poor
absorption in the body [27]. It is therefore important to consider
the effects that inappropriate storage can have on medicine
stability and ultimately seizure control in patients.
5. Conclusion
Daily antiepileptic drug therapy medication is the foundation
of epilepsy treatment [11]. DAAs have the potential to improve
adherence, especially when combined with additional adher-
ence aids, such as the use of an alarm reminder (clock, mobile
phone, reminder aids), personal reminder (member of house-
hold, carer or friend/neighbour), or calendar on the fridge to
mark off when medicine has been taken, or simplifying complex
drug regimens.
Although there are few data [9] on the stability and therefore
the efﬁcacy and safety of medicines during packing and storage,
this study provides new evidence on the stability of enteric coated
sodium valproate when repackaged in DAAs. It is important
however, that DAAs are stored in a cool, dry place protected from
light, for example inside lockable cabinets or medicines trolleys.
Monitoring the integrity of DAAs throughout the usage period is
recommended, since DAAs may be subjected to a reasonable
amount of handling and accidental rupture of the blister seals may
occur, allowing tablets to be exposed to increased levels of
humidity.
These research ﬁndings highlighting the storage of DAAs in the
refrigerator for those patients living in hot and humid climates is
signiﬁcant as it provides the ﬁrst evidence that this is a safe option.
Health care professionals can play an important role in advising
patients, carers and other members of the health care team on the
stability of medicines and the importance of packaging, storing and
using medicines correctly.
Conﬂict of interest
The authors report no conﬂict of interest.
Acknowledgements
The authors wish to acknowledge the support of James Cook
University, Grifﬁth University and King’s College London for
facilitating their student exchange program.References
[1] AMH. Australian Medicines Handbook Online. Adelaide: Australian Medicines
Handbook Pty Ltd; 2015.
[2] APHS. Australian Pharmaceutical Healthcare Systems. APHS Packaging; 2015,
www.aphspackaging.com.au [accessed 12.02.15].
[3] Bowen L, Mangan M, Haywood A, Glass B. Stability of frusemide tablets
repackaged in dose administration aids. J Pharm Pract Res 2007;37:179–81.
[4] British Pharmacopoeia. British Pharmacopoeia Online. Volume III. Formulated
preparations: speciﬁc monographs. Sodium valproate tablets; 2014.
[5] British Pharmacopoeia. British Pharmacopoeia Online. Volume V. Appendix XII
B, XII C, XVII G and XVII H; 2014.
[6] Church C, Smith J. How stable are medicines moved from original packs into
compliance aids? Pharm J 2006;276:75–81.
[7] Cramer JA, Glassman M, Rienzi V. The relationship between poor medication
compliance and seizures. Epilepsy Behav 2002;3:338–42.
[8] EasyBLIST. EasyBLIST1; 2015, https://www.easyblist.com.au [accessed
12.02.15].
[9] Elliott R. Appropriate use of dose administration aids. Aust Prescr 2014;37:46–
50.
[10] Ettinger AB, Manjunath R, Candrilli SD, Davis KL. Prevalence and cost of
nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy
Behav 2009;14:324–9.
[11] Faught E. Adherence to antiepilepsy drug therapy. Epilepsy Behav
2012;25:297–302.
[12] Flicker F, Eberle VA, Betz G. Variability in commercial carbamazepine sam-
ples—impact on drug release. Int J Pharm 2011;410:99–106.
[13] Glass B, Mangan M, Haywood A. Prochlorperazine tablets repackaged into dose
administration aids: can the patient be assured of quality? J Clin Pharm Ther
2009;34:161–9.
[14] Haywood A, Mangan M, Glass B. Stability implications of repackaging paraceta-
mol tablets into dose administration aids. J Pharm Pract Res 2006;36:25–8.
[15] ICH. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug
Substances and Products Q1A(R2). ICH Steering Committee; 2003, Available
from http://www.ich.org/ﬁleadmin/Public_Web_Site/ICH_Products/
Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf [07.07.11].
[16] Kockler J, Robertson S, Hope D, Haywood A, Glass BD. Stability of paracetamol
tablets repackaged in dose administration aids for prn use: implications for
practice. J Pharm Pract Res 2013;43:218–20.
[17] Laufs U, Rettig-Ewen V, Bohm M. Strategies to improve drug adherence. Eur
Heart J 2011;32:264–8.
[18] Llewelyn VK, Mangan MF, Glass BD. Stability of sodium valproate tablets
repackaged into dose administration aids. J Pharm Pharmacol 2010;62:838–43.
[19] Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic
drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy
Behav 2009;14:372–8.
[20] Martindale. Martindale: the complete drug reference (electronic resource).
London: Pharmaceutical Press; 2015.
[21] MedicoPak. MedicoPak1; 2015, http://www.medicopak.com.au [accessed
12.02.15].
[22] Modi AC, Rausch JR, Glauser TA. Patterns of nonadherence to antiepileptic drug
therapy in children with newly diagnosed epilepsy. JAMA 2011;305:1669–76.
[23] MPS. MPS (Medication Packaging Systems Australia Pty Ltd); 2015, http://
mps-aust.com.au/services/community-daa [accessed 12.02.15].
[24] Mylrea M, Robertson S, Haywood A, Glass BD. Stability of dispersible aspirin
tablets repacked into Dosette boxes. J Pharm Pract Res 2012;42:204–7.
[25] Perks S, Robertson S, Haywood A, Glass BD. Clozapine repackaged into Dose
Administration Aids: a common practice in Australian hospitals. Int J Pharm
Pract 2012;20:4–8.
[26] Pharmaceutical Society of Australia. Pharmaceutical Society of Australia, Dose
Administration Aids Service; 2015, http://www.psa.org.au/supporting-
practice/professional-practice-standards/dose-administration-aids-service
[accessed 12.02.15].
[27] Royal Pharmaceutical Society. Improving patient outcomes through the better
use of multi-compartment compliance aids (MCA); 2015, http://www.
rpharms.com/unsecure-support-resources/
improving-patient-outcomes-through-the-better-use-of-mcas.asp [accessed
12.02.15].
[28] Surgichem. Nomad1 Monitored Dosage System; 2015, http://www.
surgichem.co.uk/ [accessed 12.02.15].
[29] Thrifty White Pharmacy. HealthyPackRX1 by Thrifty White Pharmacy; 2015,
http://www.thriftywhite.com/Healthy_Pack_Rx.cfm [accessed 12.02.15].
[30] United States Pharmacopeia. US Pharmacopeia – National Formulary (USP 37-
NF 32) Online. <701> Disintegration; 2014.
[31] United States Pharmacopeia. US Pharmacopeia – National Formulary (USP 37-
NF 32) Online. <1146> Packaging practice – Repackaging a single solid oral
drug product into a unit-dose container; 2014.
[32] Venalink. Venalink1; 2015, http://www.venalink.co.uk [accessed 12.02.15].
[33] Webstercare. Webstercare1; 2015, http://www.webstercare.com.au
[accessed 12.02.15].
[34] Zedler BK, Kakad P, Colilla S, Murrelle L, Shah NR. Does packaging with a
calendar feature improve adherence to self-administered medication for long-
term use? A systematic review. Clin Ther 2011;33:62–73.
